Combination chemotherapy with NAB®‐paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP‐CAPABIL Pilot Study)

Background  Advanced biliary tract cancer (ABTC) is a highly aggressive malignancy, with a 5‐year overall survival of 

Saved in:
Bibliographic Details
Published in:Asia-Pacific journal of clinical oncology 2022-10, Vol.18 (5), p.e220-e226
Main Authors: Woodford, Rachel, Brungs, Daniel, Leighton, Carly, Grimison, Peter, Sjoquist, Katrin M., Becker, Therese, Robinson, Samuel, Gebski, Val, Wilson, Kate, Chantrill, Lorraine, Aghmesheh, Morteza
Format: Article
Language:English
Subjects:
advanced biliary tract cancer
Biliary tract
Cancer
Cancer therapies
Chemotherapy
cholangiocarcinoma
Cholangitis
Disease control
Gemcitabine
Immunotherapy
Malignancy
Paclitaxel
Patients
Platinum
Quality of life
second‐line treatment
Survival
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background  Advanced biliary tract cancer (ABTC) is a highly aggressive malignancy, with a 5‐year overall survival of 
ISSN:1743-7555
1743-7563
DOI:10.1111/ajco.13599